chemic
characterist
polio
isol
paralys
infant
mice
divid
group
depend
upon
differ
patholog
mice
name
coxsacki
b
virus
thereaft
extens
use
tissu
cultur
enterovirus
isol
pathogen
anim
human
echo
virus
enter
cytopathogen
human
orphan
review
mclean
artenstein
et
al
karzon
et
al
grist
et
al
final
late
virus
last
isol
patient
common
cold
classifi
rhinovirus
tyrrel
probabl
excess
virus
latter
group
circul
man
nowaday
virus
design
enteroviru
serotyp
tabl
electron
microscopi
reveal
enterovirus
small
sphere
regular
protein
capsid
structur
nm
diamet
although
member
studi
detail
capsid
compos
capsomer
pattern
cubic
symmetri
fig
icosahedron
polypeptid
molecul
per
capsid
molecular
weight
rna
approxim
x
nucleotid
sediment
coeffici
virus
rang
protein
encompass
polypeptid
exist
equimolar
amount
rna
cap
peptid
certain
virus
studi
detail
singl
larg
protein
vpo
synthes
capsid
protein
deriv
seri
proteolyt
cleavag
see
cooper
infect
uncoat
viral
rna
translat
form
giant
polyprotein
cleav
yield
capsid
protein
viral
rna
polymeras
enzym
may
exist
two
formsto
synthes
plusand
minusstrand
respectivelyi
uniqu
virusinfect
cell
respons
synthesi
virusspecifi
rna
use
rna
templat
type
type
type
type
type
type
type
type
enteroviru
type
type
type
type
type
type
type
type
type
type
type
type
type
type
type
type
addit
detail
see
mirkov
et
al
carter
ranzenhof
et
al
form
rf
multistrand
r
n
speci
known
replic
intermedi
ri
evid
ri
intermedi
viru
r
n
synthesi
consist
r
n
molecul
serv
templat
simultan
semiconserv
synthesi
sever
r
n
molecul
six
seven
polioviru
nucleotid
sequenc
complementari
templat
two
type
ri
could
existthat
use
minusstrand
r
n
produc
plusstrand
posit
ri
use
plusstrand
r
n
produc
minusstrand
neg
ri
unlik
ri
partial
sensit
action
ribonucleas
rf
highli
resist
enzym
sinc
infect
must
contain
intact
plusstrand
hydrogenbond
minusstrand
r
n
synthesi
switch
exponenti
linear
synthesi
earli
infect
time
vari
h
infect
depend
upon
input
multipl
switch
impli
concentr
posit
ri
structur
respons
synthesi
major
product
constant
throughout
latter
period
infect
could
readili
explain
synthesi
templat
posit
ri
minusstrand
ceas
switch
point
altern
produc
rate
equal
degrad
may
import
switch
occur
time
viru
r
n
begin
encapsid
form
progeni
viru
develop
sensibl
effect
strategi
immun
chemotherapi
particular
diseas
need
know
featur
viru
epidemiolog
viru
spread
commun
reservoir
infect
viru
replic
spread
host
term
poliomyel
come
polio
grey
muelo
marrow
polio
come
use
shorten
version
mean
paralysi
viru
exist
serotyp
origin
call
brunhild
lans
leon
known
type
easili
distinguish
neutral
test
although
crossimmun
occur
see
fig
tabl
second
attack
polio
rare
bodian
far
known
vaccin
one
serotyp
eg
type
protect
member
type
serotyp
although
individu
virus
may
differ
virul
boulger
et
biochem
properti
romanova
et
al
antigen
composit
nakano
et
al
polio
highli
infecti
diseas
infect
rate
may
reach
infant
class
person
contact
main
method
spread
season
incid
mark
temper
countri
outbreak
may
still
occur
winter
wherea
tropic
area
occur
throughout
entir
year
paul
follow
initi
infect
human
viru
detect
throat
secret
thorp
et
al
immunoblot
process
rabbit
antiserum
lane
antibodylabel
protein
lane
biosynthet
label
protein
lane
polioviru
type
lane
polioviru
type
lane
polioviru
type
b
immunoblot
process
rabbit
antiserum
mi
lane
antibodylabel
protein
lane
biosynthet
label
protein
lane
polioviru
type
lane
polioviru
type
lane
polioviru
type
antiserum
produc
ident
blot
see
also
tabl
faec
viru
replic
continu
tonsil
intestin
wall
region
patient
excret
viru
week
rare
week
viru
pass
region
lymph
node
probabl
reach
bloodstream
stage
clinic
evid
invas
central
nervou
system
cn
littl
doubt
viru
travel
along
neural
pathway
peripheri
cn
spread
becom
neural
cn
reach
certainli
antibodi
present
blood
viru
reach
cn
basi
success
immun
thu
appar
alreadi
induct
neutral
antibodi
serum
local
iga
antibodi
gut
incub
period
long
week
remark
featur
patholog
polio
high
select
viru
nervou
tissu
caus
rapid
widespread
damag
central
nervou
system
primari
chang
neuron
destroy
respons
nerv
cell
damag
inflammatori
reaction
oc
characterist
antibodi
polioviru
antigen
use
blot
test
thorp
et
al
bautoradiograph
band
score
order
increas
intens
weak
intens
see
also
fig
extra
detail
serolog
crossreact
see
also
ferguson
et
al
cur
infiltr
surround
tissu
polymorphonuclear
cell
lymphocyt
paralysi
occur
viru
destruct
nerv
cell
distribut
lesion
cn
seem
similar
case
polio
clinic
symptom
depend
sever
damag
nerv
cell
lassen
brain
normal
invad
particularli
brain
stem
area
baker
viru
also
isol
extraneur
tissu
eg
lymphoid
tissu
includ
peyer
patch
mesenter
lymph
node
horstmann
et
al
wenner
rabe
proport
inappar
paralyt
infect
may
high
children
adult
diseas
often
describ
biphasicminor
major
ill
minor
phase
symptom
nonspecif
malais
common
symptom
may
clear
day
major
ill
may
occur
without
preced
ill
first
symptom
mening
headach
fever
malais
vomit
abrupt
onset
christi
meningit
phase
often
conclud
week
howev
minor
person
paralysi
set
first
becom
appar
coupl
day
mening
symptom
fig
worst
case
nearli
everi
skelet
muscl
paralys
person
swallow
breath
properli
wherea
mild
case
part
one
muscl
may
affect
paralysi
lower
motor
neuron
type
flaccid
affect
muscl
develop
quickli
bulbar
poliomyel
paralysi
cranial
nerv
occur
paralysi
pharynx
featur
fact
inabl
swallow
main
clinic
characterist
bulbar
poliomyel
sign
cranial
nerv
involv
may
present
facial
weak
paralysi
flexor
muscl
neck
commonest
respir
may
deepli
disord
may
pharyng
paralysi
baker
case
paralyt
polio
full
extent
paralysi
reach
hour
although
week
pass
clinician
make
reason
prognosi
sinc
time
revers
neuron
damag
disappear
residu
irrevers
damag
assess
often
great
improv
take
place
week
end
one
month
muscl
still
paralys
probabl
remain
paralys
bulbar
polio
outlook
good
patient
still
aliv
day
sinc
pharyng
muscl
begin
show
sign
recoveri
basic
principl
clinic
care
outlin
christi
characterist
flair
accept
one
care
patient
stricken
diseas
may
cut
time
return
normal
life
ensur
everi
stage
ill
whether
life
risk
respiratori
failur
limb
made
useless
paralysi
exact
natur
disabl
analys
accur
medic
scienc
clinic
skill
measur
done
bring
aid
sovereign
art
modern
medicin
fortun
develop
polio
vaccin
given
consider
prioriti
late
follow
new
develop
tissu
cultur
technolog
review
ender
et
al
clinician
least
europ
usa
japan
australia
ussr
diagnos
polio
care
ravag
viru
children
dramat
effect
vaccin
incid
polio
illustr
european
countri
tabl
although
clincial
effect
polio
known
sinc
bc
concis
discuss
diseas
publish
underwood
surprisingli
epidem
polio
describ
last
year
would
seem
part
sanit
improv
infect
encount
later
life
paralysi
becam
promin
polio
vaccin
melnick
koprowski
et
al
salk
salk
salk
use
success
mani
countri
viru
vaccin
use
exampl
situat
remot
risk
vaccin
begin
assum
major
import
see
us
introduct
vaccin
approxim
case
poliocaus
paralysi
record
annual
number
approxim
polio
control
success
vaccin
mani
temper
countri
world
bottig
et
al
nathanson
mani
tropic
third
world
countri
sabin
john
christoph
swartz
et
al
littl
precis
inform
concern
antigen
determin
poliovirus
involv
viru
structur
function
poliovirus
classifi
three
serotyp
accord
abil
typespecif
antisera
neutral
infect
viru
exist
two
differ
antigen
form
antigen
associ
infecti
particl
c
antigen
associ
noninfecti
particl
mayer
et
al
le
bouvier
et
al
roizman
et
al
infect
associ
antigen
particl
assum
immunogen
larg
respons
product
neutral
antibodi
immunochem
work
poliovirus
well
picornavirus
carri
intact
viru
particl
capsid
protein
arrang
complex
structur
configur
immunolog
antigen
properti
individu
viru
protein
could
shown
contrast
footandmouth
diseas
viru
possibl
establish
immun
trypsinsensit
protein
vpi
induc
neutral
antibodi
meloen
et
al
see
section
immunogen
peptid
polio
vpi
relev
vaccin
singl
common
antigen
yet
describ
picornavirus
state
rememb
littl
detail
bio
chemistri
carri
mani
virus
inde
rna
hybrid
show
high
degre
homolog
certain
member
common
amino
acid
sequenc
correspond
antigen
relationship
may
exist
certainli
antigen
crossreact
note
among
certain
serotyp
coxsacki
exampl
coxsacki
b
virus
echo
virus
heterotyp
cross
reaction
occur
virus
eg
type
thorp
et
al
use
sensit
immunoblot
techniqu
describ
antigen
relationship
vp
polio
type
furthermor
certain
monoclon
antibodi
direct
toward
c
antigen
polio
type
react
vpi
viru
vpi
seem
immunodomin
regardless
form
immun
antigen
recent
report
blondel
et
al
suggest
immun
vpi
caus
product
neutral
antibodi
respect
immun
respons
polioviru
vpi
may
similar
vpi
footandmouth
diseas
viru
coxsacki
viru
meloen
et
al
beatric
et
al
although
homotyp
antibodi
bind
detect
hyperimmun
sera
heterotyp
crossreact
observ
protein
extent
view
use
either
kill
live
polio
vaccin
state
flux
present
melnick
sabin
perhap
unexpectedli
virologist
hold
domin
contrast
view
dr
salk
sabin
origin
inactiv
attenu
polio
viru
strain
respect
also
perhap
unexpectedli
sabin
enthusiast
support
widespread
use
live
vaccin
whilst
salk
confin
interest
kill
polio
vaccin
vaccin
merit
weak
may
possibl
decid
tabl
extent
judgement
rel
efficaci
use
may
depend
purpos
vaccin
campaign
world
conduct
goal
total
erad
virul
polio
viru
world
commun
possibl
anim
reservoir
viru
viru
exist
limit
number
serotyp
inacti
disappoint
result
decad
kill
vaccin
introduc
may
due
part
problem
may
correct
present
antigen
stronger
older
antigen
see
also
marsden
et
al
boulger
et
al
discuss
assess
neurovirul
polioviru
vaccin
live
virus
vaccin
virus
mutat
rare
instanc
revert
toward
vaccin
progeni
viru
spread
household
contactsa
vaccin
progeni
viru
also
spread
person
commun
agre
vaccin
certain
warmclim
countri
induct
antibodi
satisfactorili
high
proport
vaccine
difficult
accomplish
unless
repeat
dose
administ
area
even
repeat
administr
effect
contraind
immunodefici
diseas
household
associ
well
person
undergo
immunosuppress
therapi
neurovirul
suffici
caus
paralyt
polio
recipi
contact
peopl
consid
spread
commun
advantag
progeni
viru
excret
spread
vaccine
often
mutat
viru
obvious
safetytest
vaccin
licens
use
gener
popul
see
magrath
vate
vaccin
must
use
final
thrust
although
much
earlier
work
could
carri
live
vaccin
combin
live
kill
vaccin
attenu
virus
may
revert
virul
occas
nathanson
mention
genet
determin
virul
attenu
polio
viru
known
requir
extens
biochem
analysi
genom
number
attenu
virul
virus
mutant
recombin
establish
genet
basi
virul
stage
one
could
envisag
attenu
stabl
variant
could
construct
use
dna
technolog
see
chapter
hand
may
practic
produc
larg
enough
quantiti
inactiv
vaccin
cheapli
enough
total
erad
campaign
moreov
manufactur
vaccin
extend
wide
escap
virul
viru
incomplet
inactiv
vaccin
may
occur
earli
exampl
accid
cutter
affair
usa
children
contract
paralyt
poliomyel
follow
immun
insuffici
inactiv
vaccin
nathanson
langmuir
could
ad
howev
nowaday
larg
scale
manufactur
inactiv
polio
vaccin
reiniti
virus
would
chosen
less
full
virul
avoid
potenti
problem
incomplet
inactiv
salk
et
al
genet
engin
techniqu
could
explor
produc
immunogen
polio
protein
synthet
peptid
would
side
step
failur
inactiv
problem
although
synthet
techniqu
like
produc
problem
see
chapter
conclud
vaccin
success
failur
vaccin
evolutionari
blind
alley
improv
near
futur
vaccin
probabl
long
use
life
function
ahead
polio
viru
could
identifi
infect
monkey
subsequ
product
paralyt
diseas
properti
neurotrop
polio
vivo
earli
studi
cell
cultur
wrongli
interpret
indic
polio
could
replic
neural
tissu
delay
work
viru
moreov
erron
led
deduct
droplet
infect
subsequ
invas
cn
via
olfactori
nerv
end
major
point
entri
viru
human
fact
could
said
earli
studi
chemotherapi
initi
observ
sodium
alum
zinc
sulphat
picric
acid
use
unsuccess
prevent
paralysi
armstrong
harrison
sabin
et
al
olitski
sabin
schultz
gebhardt
armstrong
sabin
ward
among
first
appreci
alimentari
tract
major
site
polio
viru
replic
man
studi
establish
although
polio
viru
could
isol
fli
cockroach
antibodi
detect
cattl
chimpanze
sabin
ward
melnick
penner
sabin
fieldsteel
nevertheless
virus
maintain
natur
human
human
transmiss
epidemiolog
studi
eskimo
demonstr
antibodi
polio
persist
least
year
absenc
reinfect
natur
infect
gave
rise
complet
partial
resist
intestin
scientif
ground
work
therefor
laid
product
applic
polio
vaccin
theiler
report
laboratori
modif
neurotrop
properti
polio
koprowski
et
al
describ
first
time
immun
respons
could
produc
human
follow
infect
attenu
mous
adapt
type
polio
viru
reduc
intracerebr
virul
monkey
final
clear
demonstr
ender
et
al
three
polio
viru
type
could
replic
cell
cultur
nonnerv
tissu
see
simultan
lose
monkey
virul
tabl
open
way
extens
laboratori
studi
lead
develop
success
formalin
inactiv
also
live
attenu
polio
vaccin
salk
commenc
work
produc
inactiv
polio
vaccin
premis
circul
serum
igg
antibodi
provid
protect
clinic
sign
polio
therefor
long
kill
vaccin
induc
antibodi
sufici
quantiti
would
effect
earlier
work
laboratori
orient
toward
develop
live
attenu
virus
ceas
soon
appar
tissu
cultur
cultiv
formalininactiv
viru
immunogen
group
demonstr
viru
concentr
henc
antigen
concentr
singl
import
variabl
factor
vaccin
product
rather
inactiv
process
per
se
inactiv
formalin
ph
result
constant
rate
declin
viru
infect
first
day
howev
even
earli
stage
inactiv
lot
vaccin
vari
litr
show
variat
manufactur
satisfactori
base
line
viru
inactiv
one
manufactur
detect
day
day
anoth
product
plant
day
later
chosen
safer
cutter
incid
inactiv
proceed
lengthi
period
immunogen
decreas
henc
time
period
critic
earli
experi
monkey
establish
vaccin
given
three
divid
dose
immunogen
singl
larg
dose
tabl
summar
data
first
trial
children
antibodi
prior
immun
polio
vaccin
effect
boost
month
month
tabl
quit
clearli
era
success
immun
polio
commenc
ed
although
problem
incomplet
variabl
inactiv
viru
note
immedi
vaccin
process
scale
produc
ten
million
dose
requir
mass
immun
nathanson
langmuir
regard
product
polio
vaccin
nowaday
human
diploid
cell
use
manufactur
still
cell
substrat
consid
polio
vaccin
product
mainli
immedi
shortag
monkey
safeti
consider
addit
advantag
might
increas
yield
viru
van
wezel
et
al
marel
et
al
possibl
new
cell
substrat
subcultur
monkey
cell
rather
primari
cell
addit
newli
primat
embryo
diploid
cell
addit
human
diploid
cell
continu
cell
line
eg
vero
cell
suggest
suspens
cultur
cbntinuou
cell
line
use
sephadex
bead
ope
techniqu
perfus
trypsin
give
increas
yield
cell
denc
absenc
tumourigen
captiv
bred
monkey
fewer
adventiti
foami
virus
suitabl
sourc
kidney
cell
captur
anim
good
cell
growth
k
cell
obtain
monolay
microcarri
cultur
passag
approx
cell
gener
although
cell
stop
grow
passag
monkey
per
year
requir
produc
x
loh
dose
vaccin
although
diploid
cell
mani
favour
properti
absenc
virus
strict
control
karyotyp
chapter
requir
high
qualiti
serum
growth
less
suitabl
larg
scale
cultiv
final
vero
cell
may
suitabl
particularli
sinc
polio
viru
inactiv
formalin
final
stage
inactiv
adventiti
unknown
viru
cell
cultiv
microcarri
system
criteria
seed
polio
virus
inactiv
vaccin
includ
stabil
immunogen
replic
rate
import
factor
immunogen
type
strain
mefi
type
saukett
induc
much
higher
antibodi
level
compar
antigen
mass
type
g
mahoney
polio
also
recogn
antigen
differ
exist
within
polio
type
antigen
structur
vaccin
strain
repres
field
strain
type
viru
still
give
problem
antigen
instabl
formalin
inactiv
final
vaccin
product
cell
debri
remov
filtrat
viru
suspens
concentr
ultrafiltr
standard
use
antigen
concentr
singl
radial
diffus
techniqu
gel
filtrat
sepharos
remov
remain
serum
protein
follow
ion
exchang
deae
sephadex
use
remov
impur
origin
inactiv
techniqu
develop
salk
use
formaldehyd
elev
temperatur
prove
success
also
purifi
polio
viru
suspens
van
wezel
et
could
ad
attenu
polio
virus
could
use
nowaday
product
inactiv
polio
vaccin
thu
avoid
potenti
problem
viru
escap
inactiv
infect
paralys
recipi
sabin
cowork
attempt
attenu
highli
virul
polio
viru
mahoney
ysk
leon
cultiv
cynomolgu
kidney
tissu
cultur
howev
realis
sever
group
activ
work
problem
sever
potenti
candid
vaccin
strain
select
koprowski
et
al
ender
et
al
melnick
soon
found
mere
passag
attenu
effect
significantli
use
high
inocula
togeth
rapid
passag
favour
overgrowth
virion
abl
replic
well
nonnerv
tissu
harvest
diminish
virul
monkey
tabl
suggest
mix
popul
origin
therefor
termin
clone
carri
nonvirul
variant
three
polio
type
obtain
sabin
mark
diminut
intramuscular
oral
infect
capac
cynomolgu
monkey
note
strain
tabl
monkey
produc
antibodi
respons
infect
sabin
select
variant
mous
passag
mahoney
strain
type
potenti
use
vaccin
strain
earli
tent
trial
volunt
confirm
attenu
virus
tabl
expert
committe
poliomyel
recommend
larg
scale
trial
newli
develop
formalininactiv
vaccin
particularli
well
control
trial
usa
franci
et
al
demonstr
efficaci
safeti
new
vaccin
howev
sabin
develop
sever
live
attenu
candid
vaccin
virus
sinc
want
interfer
still
progress
trial
salk
vaccin
usa
initi
larg
scale
trial
eur
ope
stage
genet
basi
virul
new
polio
strain
establish
least
tent
sever
phenotyp
virolog
marker
cosegreg
virul
observ
thu
attenu
polio
strain
often
possess
ts
ca
properti
fact
appear
retrospect
sinc
earli
tissu
cultur
passag
experi
attenu
virus
carri
low
temperatur
c
may
also
increas
select
pressur
ts
attenu
viru
subpopul
sabin
larg
scale
polio
immun
carri
europ
collabor
larg
activ
virolog
group
leningrad
repres
retrospect
classic
seri
experi
scientif
benefit
mankind
initi
small
group
children
immun
increas
clinic
laboratori
experi
show
advers
effect
campaign
widen
thu
earli
clinic
trial
carri
sabin
live
vaccin
viru
baltic
republ
latvia
lithuania
esthonia
chumakov
et
al
twenti
seven
thousand
individu
immun
vaccin
provid
sabin
million
peopl
fed
first
passag
materi
grown
ussr
first
cycl
immun
carri
januarymarch
tabl
almost
half
suscept
popul
lithuania
receiv
live
viru
vaccin
convinc
proof
highli
immunogen
characterist
viru
obtain
trival
mixtur
also
use
effect
children
develop
antibodi
three
type
separ
studi
smorodintsev
et
al
also
use
cautiou
approach
april
april
observ
vaccin
children
contact
vaccin
children
may
children
januari
march
x
fed
vaccin
viru
tabl
show
ill
immun
children
nonimmun
control
riga
n
clinic
polio
detect
vaccin
group
intern
control
group
earli
experi
smorodintsev
leningrad
also
establish
mark
increas
virul
occur
humanhuman
passag
attenu
viru
es
smorodintsev
et
vaccin
began
wide
use
tabl
howev
earli
studi
soon
becam
appar
problem
vaccin
take
could
occur
countri
poor
hygien
mani
enterovirus
present
gut
could
interfer
replic
polio
vaccin
viru
sabin
sever
develop
countri
virtual
erad
polio
includ
exampl
usa
ussr
uk
scandinavia
bottig
fig
certain
western
eastern
european
countri
howev
polio
still
com
mon
underdevelop
countri
quandari
erad
live
polio
vaccin
often
work
errat
less
satisfactori
countri
chandra
swartz
et
al
hale
et
al
also
inactiv
polio
vaccin
may
produc
herd
immun
assum
import
sinc
countri
faecalor
rout
transmiss
common
inactiv
polio
may
reduc
transmiss
via
pharyng
rout
gelfand
et
al
chin
et
al
therefor
research
clearli
need
decis
made
strategi
control
erad
poliomyel
develop
countri
meanwhil
howev
might
learn
use
data
experi
erad
polio
certain
countri
like
usa
use
live
vaccin
scandinavia
use
inactiv
vaccin
incid
polio
usa
drop
steepli
level
case
year
case
year
similar
figur
obtain
uk
scandinavia
fig
natur
occur
poliomyel
due
indigen
wild
polioviru
essenti
disappear
usa
nathanson
nevertheless
children
year
age
usa
consid
remain
suscept
polio
vaccin
coverag
tabl
success
erad
polio
usa
achiev
mainli
use
attenu
vaccin
tabl
continu
problem
vaccin
albeit
small
number
vaccineassoci
case
poliomyel
schonberg
et
al
approxim
paralyt
case
per
million
vaccine
usa
million
children
immun
yearli
paralyt
case
expect
caus
vaccin
viru
one
third
occur
recipi
vaccin
two
third
contact
mainli
adult
present
estim
million
children
usa
still
suscept
polio
type
provid
substanti
pool
suscept
epidem
occur
sweden
finland
exampl
problem
outbreak
polio
unimmun
pocket
amish
fundamentalist
protest
case
polio
occur
chapter
posterad
era
usa
constant
risk
introduct
wild
type
viru
would
seem
unnecessari
chang
vaccin
present
usa
inactiv
polio
vaccin
could
use
benefit
immunocompromis
individu
davi
et
adult
contact
children
immun
live
vaccin
boost
immun
adult
travel
abroad
import
yet
incomplet
answer
question
whether
inactiv
polio
vaccin
could
reduc
spread
viru
alimentari
tract
circul
viru
commun
earli
experi
inactiv
polio
vaccin
usa
would
suggest
inactiv
polio
vaccin
inhibit
viru
circul
marin
et
al
thu
studi
polio
outbreak
singl
town
high
low
socioeconom
group
show
cluster
latter
group
case
former
group
also
polio
viru
isol
sewag
infrequ
upper
class
area
frequent
lower
class
area
outbreak
rhode
island
polio
cluster
two
lower
class
area
pawtucket
high
attack
rate
wherea
area
remain
free
polio
sewag
inactiv
lower
class
area
contain
type
polio
like
interpret
better
vaccin
affluent
neighbourhood
subject
silent
ecolog
spread
viru
time
intens
epidem
low
class
area
recent
evid
netherland
polio
outbreak
even
without
immun
barrier
provid
transmiss
polio
inactiv
vaccin
although
evid
infect
unimmun
classmat
case
widespread
transmiss
viru
occur
mention
seem
quit
possibl
inactiv
polio
vaccin
inhibitori
effect
pharyng
excret
polio
viru
gelfand
et
al
follow
famili
receiv
inactiv
polio
vaccin
wild
polio
introduc
household
previou
immun
children
influenc
viru
spread
faecal
excret
viru
vaccin
unvaccin
person
contrast
spread
polio
limit
upper
econom
household
possibl
explan
inactiv
vaccin
reduc
excret
pharyng
viru
whilst
level
hygien
home
high
enough
limit
spread
viru
faecal
oral
rout
paralyt
polio
still
occur
countri
world
incid
rate
vari
minut
per
million
person
per
year
usa
case
persist
paralysi
per
million
person
per
year
certain
african
countri
recent
lame
survey
techniqu
pioneer
expand
programm
immun
chapter
chang
previou
idea
poliomyel
tropic
area
clear
residu
paralyt
polio
burma
egypt
thailand
indonesia
ivori
coast
brazil
india
yemen
niger
higher
prevaccin
era
usa
sweden
old
dogma
tropic
infect
rate
polio
high
paralysi
rate
low
increas
incid
paralyt
diseas
relat
emerg
epidem
improv
standard
live
reflect
diminish
infant
mortal
rate
may
longer
hold
sabin
lame
certain
develop
countri
found
caus
poliomyel
viru
absenc
immun
programm
school
age
children
disabl
polio
estim
take
account
afflict
die
recov
tarantola
obvious
world
scale
seriou
imbal
regard
incid
polio
requir
correct
high
prioriti
complet
list
reason
calamat
differ
countri
absolut
clear
disagr
exist
current
scientif
literatur
import
reason
absenc
modern
medic
social
infrastructur
certain
develop
countri
even
although
scientif
debat
may
continu
merit
drawback
underdevelop
countri
inactiv
versu
attenu
polio
vaccin
nevertheless
clear
studi
sabin
other
vigor
concert
rapid
immun
campaign
sabin
use
oral
attenu
polio
vaccin
stop
polio
tropic
semitrop
underdevelop
countri
earli
cuba
show
way
annual
mass
vaccin
campaign
two
sunday
year
children
five
year
age
regardless
number
dose
might
previous
annual
mass
vaccin
make
possibl
reach
extrem
high
proport
children
necessari
break
chain
infect
vaccin
spread
time
wild
polio
enterovirus
remain
domin
commun
anoth
exampl
brazil
organ
armi
volunt
vaccin
almost
children
million
year
age
twice
year
singl
day
june
august
august
octob
precipit
drop
report
case
follow
sabin
altern
option
use
dose
vaccin
john
found
multipl
dose
convent
oral
vaccin
contain
tcidso
type
five
dose
requir
give
x
seroconvers
approach
requir
good
organ
mass
campaign
fangchou
et
al
describ
polio
control
recent
subtrop
area
china
use
oral
attenu
vaccin
guangxi
autonom
region
popul
million
person
appar
healthi
children
found
heavili
infect
nonpolio
enterovirus
even
late
sever
polio
epidem
detect
sinc
polio
vaccin
rate
still
low
especi
rural
area
intens
campaign
initi
use
barefoot
doctor
special
immun
team
rural
area
incid
polio
sinc
declin
per
person
fangchou
et
al
conclud
key
elimin
paralyt
poliomyel
commun
power
leadership
author
public
health
provid
effect
administr
guidanc
measur
train
organ
health
personnel
altern
approach
use
kill
polio
vaccin
earli
studi
beal
show
vaccin
given
month
booster
one
year
gave
high
seroconvers
rate
polio
mix
diphtheria
tetanu
pertussi
vaccin
thu
protect
diseas
one
immun
cours
immun
mali
indonesia
unit
current
use
polio
vaccin
result
essenti
seroconvers
probabl
singl
dose
month
provid
immunolog
memori
subsequ
contact
natur
viru
would
boost
immun
review
beal
see
also
tabl
krishnan
et
al
evalu
immunogen
efficaci
inactiv
polio
vaccin
india
infant
given
quadrupl
vaccin
incorpor
polio
diptheriapertussistetanu
total
babi
age
week
immun
three
dose
vaccin
contain
antigen
unit
polio
type
respect
interv
week
overal
seroconvers
rate
polioviru
type
respect
otherwis
advers
effect
matern
antibodi
immun
respons
reduc
increas
interv
dose
week
total
case
paralyt
polio
pure
spinal
paralysi
case
spinal
involv
although
case
one
lower
limb
paralys
report
usa
period
repres
dramat
decreas
case
report
year
therefor
attack
rate
paralyt
polio
declin
high
case
per
popul
case
per
popul
case
associ
epidem
endem
import
immun
defici
person
particular
interest
group
vaccineassoci
case
examin
occur
recipi
oral
polio
vaccin
occur
household
contact
vaccine
nonhousehold
contact
perhap
expect
season
distribut
case
case
year
age
compar
adult
case
observ
analysi
polio
viru
isol
oligonucleotid
map
show
isol
vaccin
case
vaccinelik
oligonucleotid
spot
pattern
see
chapter
detail
polio
case
analyz
care
involv
polio
type
type
type
type
respons
epidem
associ
case
respons
vaccin
associ
case
often
associ
type
type
virus
recent
analysi
epidemiolog
characterist
paralyt
polio
case
usa
illustr
tabl
left
last
chapter
indic
potenti
new
develop
polio
vaccin
either
regard
live
inactiv
vaccin
taken
mani
year
establish
safeti
exist
polio
vaccin
therefor
unlik
new
technic
develop
introduc
quickli
unless
unlik
repres
strike
scientif
breakthrough
exampl
imrnunogen
ie
produc
crossprotect
varieti
enterovirus
mark
reduct
cost
rememb
live
polio
vaccin
cheap
extens
discuss
new
data
present
chapter
shall
content
brief
review
typic
recent
data
polio
immunogen
peptid
sinc
area
intens
investig
present
recent
emini
et
al
synthes
five
peptid
contain
amino
acid
sequenc
type
polioviru
structur
protein
vpi
peptid
abl
prime
immun
system
rabbit
subsequ
chalieng
singl
inocul
whole
polio
viru
produc
long
last
viru
neutral
igg
antibodi
respons
essenti
data
summar
tabl
sequenc
chosen
hydrophil
analysi
protein
sequenc
sequenc
variat
analysi
obtain
compar
amino
acid
sequenc
vpi
three
polio
serotyp
assum
hydrophil
region
vpi
like
expos
viru
surfac
four
five
peptid
recogn
neutral
monoclon
antibodi
rais
intact
type
polioviru
singl
peptid
elicit
viru
neutral
antibodi
coupl
carrier
protein
final
peptid
abl
prime
anim
subsequ
react
rapidli
immun
whole
polio
viru
prime
specif
sens
prime
occur
homolog
type
viru
possibl
prime
alon
might
give
suffici
protect
polioviru
infect
major
studi
polioviru
antigen
site
report
minor
et
al
sinc
vaccin
success
prevent
diseas
polio
rather
littl
new
work
initi
recent
year
studi
specif
inhibitor
polio
viru
replic
although
import
studi
carri
earlier
guanidin
hydroxybenzimidazol
compound
see
contrast
inhibitor
rhinovirus
sought
extens
although
without
success
recent
review
tyrrel
et
al
reed
littl
work
carri
rhinoviru
vaccin
mainli
awesom
problem
multipl
serotyp
earli
work
hollinshead
smith
describ
inhibitori
effect
benzimidazol
hbb
fig
polio
type
replic
mice
death
anim
prevent
earli
tissu
cultur
experi
establish
compound
exert
antivir
effect
vitro
simpli
virucid
toxic
effect
uninfect
tissu
cultur
cell
tamm
neme
compound
one
first
antivir
molecul
discov
howev
hbb
show
unwant
characterist
becom
familiar
specialist
work
later
antiviralsdrug
resist
viru
mutant
could
isol
rel
eas
compound
narrow
antivir
spectrum
less
limit
enterovirus
tabl
hbb
act
first
hour
polio
viru
infect
cell
although
precis
point
action
known
viru
adsorpt
penetr
uncoat
howev
affect
viru
rna
protein
synthesi
inhibit
viru
macromolecular
synthesi
thought
target
site
inhibit
cessat
viru
rna
synthesi
eventu
stop
viral
protein
synthesi
interpret
rather
conflict
data
hbb
inhibit
synthesi
viru
direct
rna
polymeras
turn
halt
replic
viru
rna
lead
inhibit
synthesi
viral
capsid
polypeptid
altern
experi
suggest
hbb
inhibit
viral
rna
synthesi
therebi
inhibit
replic
infecti
viru
hbb
significantli
delay
develop
enteroviru
cpe
mk
cell
although
cell
ultim
succumb
viru
induc
cpe
presum
coxsacki
virus
rhinovirus
viru
induc
cell
protein
rna
shut
product
infecti
viru
significantli
inhibit
hbb
vitro
log
ld
ml
inhibit
certain
enterovirus
howev
mani
antivir
much
less
antivir
effect
note
vivo
larg
number
deriv
hbb
investig
viru
inhibitori
effect
tamm
et
al
found
hydroxybenzyl
group
posit
benzimidazol
ring
critic
import
also
replac
benzimidazol
nucleu
hbb
imidazol
ring
result
complet
loss
antivir
activ
certain
substitut
deriv
propyl
methylpropyl
iphenylhbb
activ
select
vitro
hbb
thu
select
viru
inhibitori
activ
hbb
depend
upon
overal
geometri
molecul
structur
modif
lead
loss
viral
inhibitori
activ
select
earli
rightsel
et
al
publish
detail
inhibit
polio
viru
guanidin
soon
afterward
familiar
drug
resist
even
drug
depend
mutant
detect
loddo
et
al
mani
enterovirus
inhibit
vitro
guanidin
see
tabl
fig
nevertheless
antivir
spectrum
compound
sever
restrict
rna
virus
guanidin
direct
virucid
effect
enteroviru
attach
penetr
inhibit
crowther
melnick
inhibit
effect
begin
midway
viru
latent
phase
continu
reproduct
cycl
princip
site
guanidin
action
appear
synthesi
viral
rna
one
step
may
affect
review
tershak
et
al
caliguiri
tamm
polio
rna
polymeras
inhibit
vitro
presum
initi
viral
rna
synthesi
occur
cell
free
extract
result
complet
rna
chain
process
synthesi
extract
crude
enzym
hough
recent
pure
prepar
picornaviru
polymeras
util
exogen
viral
rna
obtain
could
test
initit
synthesi
viral
rna
seem
depress
guanidin
releas
complet
rna
chain
restrict
current
data
would
point
initi
step
viral
rna
synthesi
site
action
guanidin
tershak
et
al
addit
guanidin
exert
mild
conform
chang
viral
protein
specif
could
due
specif
amino
acid
sequenc
picornavirus
compar
cell
protein
protein
virus
possibl
synthesi
encapsid
viral
rna
requir
capsid
subunit
vpg
interact
guanidin
would
caus
multipl
aberr
guanidin
combin
hbb
use
success
treat
echoviru
type
coxsacki
infect
newborn
mice
although
neither
compound
alon
effect
egger
theoret
level
inhibitor
pm
hbb
guanidin
sever
acycl
diketon
shown
inhibit
replic
equin
picornavirus
diana
et
al
arildon
phenoxi
emerg
promis
candid
antivir
broad
spectrum
vitro
antivir
activ
equin
rhinoviru
interestingli
hsv
tabl
compound
arildon
compos
diketon
separ
substitut
benzen
ring
alkyl
chain
carbon
stabl
heat
virtual
insolubl
water
drawback
substitu
benzen
ring
contribut
lipophil
substitut
addit
hydrophob
substitu
decreas
antivir
activ
compound
shorter
longer
alkyl
chain
decreas
antivir
activ
review
mcsharri
pancic
compound
thought
inhibit
polio
replic
prevent
intracellular
uncoat
virion
mcsharri
et
al
perhap
stabil
capsid
protein
undergo
conform
chang
requir
uncoat
releas
virion
rna
isol
drug
resist
mutant
polio
also
suggest
direct
antivir
effect
viru
certainli
arildon
appear
stabil
polio
presenc
heat
alkali
tabl
arildon
assess
abil
prevent
paralysi
death
mice
infect
intracerebr
lethal
dose
human
polioviru
type
mckinlay
et
al
intraperiton
administr
arildon
suspend
gum
tragacanth
prevent
paralysi
death
dosedepend
manner
minim
inhibitori
dose
mgkg
twice
daili
protect
anim
viru
challeng
excess
twenti
lethal
dose
tabl
oral
medic
arildon
solubil
corn
oil
similarli
effect
prevent
poliovirusinduc
paralysi
death
arildon
therapeut
effect
even
intraperiton
medic
delay
h
postinfect
analysi
viru
titr
central
nervou
system
tissu
anim
infect
lethal
dose
demonstr
arildon
reduc
titr
brain
spine
approxim
log
pfu
per
g
tissu
respect
impli
direct
inhibit
viru
replic
respons
host
surviv
howev
anim
model
depend
direct
inocul
polio
cn
therefor
relev
studi
human
polio
must
await
studi
note
acut
oral
ldso
arildon
mice
excess
gkg
monkey
rat
medic
daili
week
mgkg
show
toxic
reaction
summari
compound
excit
littl
interest
clinician
success
polio
vaccin
rel
lack
interest
enterovirus
main
use
present
appear
laboratori
studi
enteroviru
replic
includ
genet
marker
minor
respiratori
infect
common
cold
one
commonest
viral
diseas
uk
temper
even
subtrop
countri
addit
caus
exacerb
chronic
condit
asthma
chronic
bronchiti
cardiac
failur
review
andrew
hopesimpson
mention
present
crossreact
antigen
determin
detect
among
group
virus
henc
develop
effect
vaccin
would
difficult
sinc
virus
close
relat
regard
physicochem
properti
presum
biochemistri
receptor
site
etc
would
appear
logic
place
emphasi
develop
antivir
drug
interferon
pharmaceut
group
search
new
antivir
includ
typic
rhinovirus
antivir
screen
programm
latter
work
done
tissu
cultur
system
absenc
anim
model
human
rhinovirus
suitabl
compound
test
volunt
pharmacolog
properti
nontox
compound
test
exampl
common
cold
research
unit
harvard
hospit
shlisburi
compar
unit
leningrad
houston
volunt
uk
unit
age
year
arriv
unit
given
medic
examin
preliminari
serum
sampl
taken
subsequ
use
estim
level
antiviru
antibodi
bear
reed
experiment
period
volunt
isol
pair
selfcontain
apart
physic
contact
allow
person
fig
subject
symptom
object
criteria
use
grade
reaction
induc
experiment
virus
rang
mild
trivial
reaction
mild
local
symptom
moder
local
constitut
symptom
sever
febril
unpleas
reaction
necessit
bed
rest
number
paper
handkerchief
use
day
count
may
often
increas
baselin
per
day
per
day
symptom
cold
day
quarantin
antivir
medic
start
volunt
infect
rhinoviru
intranas
fig
nasal
wash
taken
sever
day
thereaft
viru
reisol
studi
drug
may
administ
local
spray
oral
latter
case
must
evid
enough
compound
reach
secret
upper
respiratori
tract
hand
mucociliari
clearanc
mechan
effici
may
rapidli
reduc
local
concentr
nasal
administ
drug
reed
summar
earlier
trial
volunt
specif
antivir
interferon
tabl
see
also
chapter
gener
guanidinetyp
molecul
given
disappoint
result
volunt
recent
benzimidazol
shown
mild
antivir
effect
enviroxim
isopropyl
sulphonyl
phenyl
keton
oxim
tabl
fig
compound
complet
suppress
plaqu
format
vitro
rhinovirus
type
tabl
moreov
enviroxim
inhibit
fur
fig
accommod
salisburi
common
cold
unit
bear
reed
ther
rhinoviru
serotyp
least
log
unit
ugml
enviroxim
equal
effect
human
embryo
fibroblast
hela
cell
also
human
embryo
nasal
trachea
organ
cultur
concentr
pgml
clinic
trial
tabl
intranas
oral
administr
compound
use
sever
cold
reduc
fig
although
borderlin
statist
signific
rememb
also
volunt
given
minimum
viru
challeng
presenc
maximum
near
toxic
level
drug
even
condit
antivir
effect
strike
nevertheless
repres
first
synthes
antivir
coumpound
detect
antirhinoviru
effect
man
howev
trial
enviroxim
also
carri
hayden
gwaltney
unabl
detect
antivir
effect
tabl
intranas
administr
enviroxim
aerosol
spray
associ
drug
level
nasal
secret
h
later
averag
higher
inhibitori
rhinovirus
vitro
pglml
howev
administr
intranas
enviroxim
one
spray
per
nostril
five
time
per
day
suscept
volunt
begin
day
continu
day
viru
exposur
significantli
reduc
infect
ill
due
experiment
induc
rhinoviru
type
infect
combin
result
two
separ
trial
yield
infect
rate
iooo
pla
cebotr
enviroximetr
subject
approxim
onehalf
volunt
group
seroconvers
challeng
viru
overal
placebotr
enviroximetr
subject
develop
cold
signific
differ
symptom
score
nasal
mucu
weight
number
nasal
tissu
use
observ
two
group
twothird
enviroximetr
volunt
note
intranas
irrit
immedi
spray
compar
onethird
placebotr
subject
anoth
recent
investig
compound
dichloroflavan
fig
shown
detect
antirhinoviru
effect
volunt
fig
tabl
although
compound
antirhinoviru
activ
vitro
tabl
could
attribut
pharmacolog
problem
perhap
low
concentr
reach
nasal
mucosa
nitrobenzen
deriv
found
inhibit
plaqu
format
cyto
pathic
effect
picornavirus
tabl
concentr
affect
cell
growth
torney
et
al
compound
directli
inactiv
viru
inhibit
actinomycin
dresist
uptak
cell
infect
coxsacki
viru
rhinoviru
wherea
incorpor
uninfect
cell
inhibit
three
picornavirus
echoviru
type
polioviru
type
rhinoviru
type
la
made
photosensit
neutral
red
appear
caus
signific
reduct
loss
photosensit
uncoat
first
h
infect
author
conclud
appear
inhibit
earli
event
viru
replic
uncoat
requir
synthesi
viral
rna
multipl
growth
cycl
experi
pg
per
ml
caus
reduct
viru
yield
least
log
tissu
cultur
infecti
dose
per
r
isol
chines
medicin
herb
found
potent
antivir
activ
select
inhibit
replic
human
picornavirus
rhinovirus
coxsacki
virus
tissu
cultur
tabl
tabl
critic
time
inhibit
rhinoviru
replic
compound
h
viru
adsorpt
ie
earli
stage
viru
replic
markedli
inhibit
coxsacki
viru
rhinoviru
rna
synthesi
infect
hela
cell
cellfre
system
use
rna
polymeras
complex
isol
infect
cell
infect
cell
rna
polymeras
complex
form
presenc
drug
therefor
suggest
ro
interfer
process
viral
replic
occur
viral
uncoat
initi
viral
rna
synthesi
furthermor
studi
variou
analog
relat
led
identif
ro
new
differ
type
antivir
agent
ro
high
activ
rhinovirus
activ
picornavirus
rhinoviru
serotyp
test
suscept
compound
hela
cell
cultur
concentr
ro
inhibit
type
rhinoviru
pglml
wherea
cytotox
concentr
pglml
ro
inactiv
rhinovirus
direct
dose
time
temperaturedepend
fashion
conclud
inactiv
may
associ
bind
agent
specif
site
rhinoviru
capsid
final
end
near
begin
attempt
chemotherapi
rhinovirus
name
interferon
merigan
et
al
show
x
unit
pg
approxim
partial
purifi
human
leukocyt
interferon
could
protect
volunt
infect
rhinoviru
type
time
experi
use
great
proport
total
world
suppli
interferon
pretreat
treatment
prolong
classic
experi
repeat
group
three
mice
infect
intraperiton
coxsackieviru
treat
oral
four
time
ro
infect
use
highli
purifi
tenfold
interferon
use
rhinoviru
type
scott
et
al
data
summar
tabl
symptom
markedli
reduc
viru
infect
seroconvers
prevent
possibl
interferon
dehi
onset
cold
still
long
way
go
common
cold
vanquish
infect
caus
enteroviru
uniqu
posit
virolog
one
two
human
virus
pandem
epidemiolog
influenza
still
head
record
classic
exampl
viru
infect
first
describ
chatterje
et
al
ghana
diseas
incub
period
short
h
call
apollo
diseas
local
outbreak
coincid
time
apollo
land
moon
within
year
outbreak
occur
japan
kono
new
picornaviru
isol
conjunctiv
scrape
enteroviru
spread
almost
around
world
hierholz
et
al
likar
et
al
mirkov
et
al
although
apollo
diseas
usual
rather
benign
complet
recoveri
within
week
neurolog
complic
nevertheless
describ
affect
case
paralys
case
men
typic
neurolog
phase
begin
week
onset
conjunct
acut
hypoton
asymmetr
proxim
paralysi
lower
limb
fever
malais
nerv
root
pain
cranial
nerv
paralysi
often
note
paralysi
may
perman
affect
henc
near
futur
viru
may
import
candid
vaccin
develop
chemoprophylaxi
epidem
reach
enorm
proport
tabl
million
case
exampl
calcutta
diseas
frequent
seen
young
adult
common
children
although
serolog
evid
show
infect
occur
less
frequent
children
tabl
condit
poor
hygien
overcrowd
rapid
extens
spread
occur
enteroviru
seldom
found
faec
patient
virus
rather
fastidi
cultiv
point
view
may
isol
human
diploid
fibroblast
organ
cultur
human
embryon
conjunctiva
pathogen
suckl
mice
sensit
kinet
neutral
test
shown
serolog
differ
occur
among
isol
enteroviru
higgin
apollo
diseas
excel
exampl
new
diseas
occur
man
result
previous
unknown
viru
eg
marburg
viru
also
member
group
virus
behav
previous
undescrib
fashion
coxsacki
enteroviru
caus
diseas
previous
recogn
characterist
enterovirus
present
vaccin
specif
treatment
exist
fact
even
live
inactiv
vaccin
develop
clear
rout
administr
exam
ple
would
effect
specif
antivir
could
prevent
secondari
paralysi
syndrom
especi
rather
long
interv
conjunct
paralysi
consid
larg
number
person
would
treat
prevent
singl
case
paralysi
certain
arbovirus
see
chapter
resourc
might
use
divert
alter
improv
hygien
live
condit
develop
countri
highest
attack
rate
record
polio
well
control
develop
countri
use
ive
ew
countri
inactiv
vaccin
research
work
intensifi
use
genet
engin
techniqu
produc
live
attenu
virus
defin
stabl
mutat
prevent
revers
virul
also
produc
immunogen
oligopeptid
protein
new
gener
inactiv
polio
vaccin
chemotherapi
therefor
requir
polio
infect
contrast
vaccin
develop
rhinoviru
infect
vaccin
thought
use
unless
broadli
react
antigen
determin
locat
sever
interest
weakli
effect
antivir
compound
select
rhinovirus
major
research
area
present
studi
continu
also
interferon
toxic
problem
look
less
interest
present
sequenc
biochem
data
avail
sever
addit
enteroviru
strain
includ
pandem
enteroviru
type
hepat
could
open
new
possibl
antivir
vaccin
eg
synthet
peptid
near
futur
present
littl
attent
paid
prevent
spread
mani
import
enterovirus
coxsacki
echo
viru
group
although
virus
result
seriou
neurolog
sequela
resembl
polio
virus
regard
